• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ:REGN)

    762.63 +24.29 (+3.29%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Regeneron Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    News headline image
    Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Regeneron Reports Second Quarter 2026 Financial and Operating Results
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    Did You Lose Money Investing in Regeneron Pharmaceuticals, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against REGN
    San Diego, California--(Newsfile Corp. - July 23, 2026) - Robbins LLP reminds stockholders that a class action was filed on... 
    Via Newsfile
    Topics Earnings
    News headline image
    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law
    From Bleichmar Fonti & Auld LLP
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN
    From DJS Law Group
    Via Business Wire
    News headline image
    REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    REGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    Investor Notice: Robbins LLP Informs Investors of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit
    From Robbins LLP
    Via Business Wire
    News headline image
    Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
    Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needs 
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN): Grabar Law Office is Investigating Claims on Your
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Important Notice to Long-Term Shareholders of Molina Healthcare, Inc. (NYSE: MOH); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Grabar Law Office is Investigating Claims on
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.